A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Bumetanide (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms CUREPARK
- Sponsors B&A Therapeutics
Most Recent Events
- 09 Apr 2019 New trial record